Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement

Medical Oncology - Tập 28 - Trang 1589-1595 - 2010
Barbara Pienkowska-Grela1, Grzegorz Rymkiewicz2, Beata Grygalewicz1, Renata Woroniecka1, Paulina Krawczyk1, Katarzyna Czyz-Domanska3, Jan Walewski3
1Cytogenetic Laboratory, MSCM Cancer Centre and Institute, Warsaw, Poland
2Flow Cytometry Laboratory, MSCM Cancer Centre and Institute, Warsaw, Poland
3Department of Lymphoprolipherative Disease, MSCM Cancer Centre and Institute, Warsaw, Poland

Tóm tắt

Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by specific morphological and immunophenotypic features. The basic genetic feature of BL is the rearrangement of MYC gene, visible as t(8;14)(q24;q32) translocation or its variant. However, some lymphomas with characteristic BL morphology are nowadays diagnosed as B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL (Inter-DLBCL/BL) for biological or clinical reasons. We present four lymphomas without the MYC rearrangement presented typical Burkitt morphology, FCM immunophenotype with some deviations when compared to a typical BL. The cases were finally diagnosed as Inter-DLBCL/BL. All of them presented a recurrent abnormality within the chromosome 11: dup(11)(q23q13). We suppose that the dup(11)(q23q13), in absence of the MYC gene rearrangement, is connected with borderline lymphomas with a morphology similar or identical to that of the Burkitt lymphoma. Identifying such an aberration may be helpful in the diagnostics of Inter-DLBCL/BL eventually forming a distinct subgroup of lymphomas.

Tài liệu tham khảo

Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42. Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6. Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4. Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91. Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8. Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80. Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20. Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21. Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4. Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program. http://asheducationbook.hematologylibrary.org/cgi/content/full/2008/1/341. Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30. Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005. Mitelman Database of Chromosome Aberrations in Cancer, The Cancer Genome Anatomy Project http://cgap.nih.gov/chromosomes/Mitelman. Accessed 14 July 2009. Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52. Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50. Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90. Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03. Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.